2020
DOI: 10.1111/dth.13857
View full text
|
Sign up to set email alerts
|
Share

Abstract: Hydroxychloroquine is the β-hydroxylated analogue of chloroquine which has garnered unprecedented attention as a potential drug for COVID-19, following preliminary reports on its in vitro activity against the virus. Hydroxychloroquine (half-maximal effective concentration [EC50] = 0.72 μM) was found to be more potent than chloroquine (EC50 = 5.47 μM) in vitro against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). 1 By contrast, Liu et al found a lower EC50 for hydroxychloroquine with a similar 5…

Expand abstract